Display options
Cite
Radwan MF, Dalby KN, Kaoud TS. Propyphenazone-based analogues as prodrugs and selective cyclooxygenase-2 inhibitors. ACS Med Chem Lett. 2014;5(9):983-8doi: 10.1021/ml500156v.
Radwan, M. F., Dalby, K. N., & Kaoud, T. S. (2014). Propyphenazone-based analogues as prodrugs and selective cyclooxygenase-2 inhibitors. ACS medicinal chemistry letters, 5(9), 983-8. https://doi.org/10.1021/ml500156v
Radwan, Mohamed F, et al. "Propyphenazone-based analogues as prodrugs and selective cyclooxygenase-2 inhibitors." ACS medicinal chemistry letters vol. 5,9 (2014): 983-8. doi: https://doi.org/10.1021/ml500156v
Radwan MF, Dalby KN, Kaoud TS. Propyphenazone-based analogues as prodrugs and selective cyclooxygenase-2 inhibitors. ACS Med Chem Lett. 2014 Jun 23;5(9):983-8. doi: 10.1021/ml500156v. eCollection 2014 Sep 11. PMID: 25221653; PMCID: PMC4160749.
Copy Download .nbib Format: NLM
Share it on

ACS Med Chem Lett. 2014 Jun 23;5(9):983-8. doi: 10.1021/ml500156v. eCollection 2014 Sep 11.

Propyphenazone-based analogues as prodrugs and selective cyclooxygenase-2 inhibitors.

ACS medicinal chemistry letters

Mohamed F Radwan, Kevin N Dalby, Tamer S Kaoud

Affiliations

  1. Department of Medicinal Chemistry, Faculty of Pharmacy, Minia University , 61519 Minia, Egypt ; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, King Abdulaziz University , Jeddah 21589, Kingdome of Saudi Arabia.
  2. Division of Medicinal Chemistry, College of Pharmacy, The University of Texas at Austin , Austin, Texas 78712, United States.
  3. Department of Medicinal Chemistry, Faculty of Pharmacy, Minia University , 61519 Minia, Egypt ; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, King Abdulaziz University , Jeddah 21589, Kingdome of Saudi Arabia ; Division of Medicinal Chemistry, College of Pharmacy, The University of Texas at Austin , Austin, Texas 78712, United States.

PMID: 25221653 PMCID: PMC4160749 DOI: 10.1021/ml500156v

Abstract

Improving the gastrointestinal safety profile of nonsteroidal anti-inflammatory drugs (NSAIDs) is an important goal. Herein, we report two strategies, using the nonacidic propyphenazone structure, with potential to overcome the side effects of NSAIDs. Propyphenazone was employed to temporarily mask the free acid group of the widely used NSAIDs ibuprofen, diclofenac, and ketoprofen to develop three mutual prodrugs hypothesized to have minimal GI irritation. The three prodrugs exhibit in vivo anti-inflammatory and analgesic activities with improved potency over each parent drug when compared to a nonhydrolyzable control betahistine-propyphenazone (BET-MP). Additionally, ANT-MP formed by the irreversible coupling of propyphenazone and 4-aminoantipyrine, displayed exceptional COXII selectivity (COXII IC50 of 0.97 ± 0.04 μM, compared to no observed inhibition of COXI at 160 μM). Inhibition of COXII suppresses inflammatory diseases without affecting COXI-mediated GI tract events. ANT-MP exhibited maximal analgesic effect when tested in vivo in an abdominal writhing assay (100% protection) and its anti-inflammatory activity showed a peak at 2 h in a carrageenan-induced paw edema model. Its unique selectivity toward the COXII enzyme was investigated using molecular modeling techniques.

Keywords: NSAIDs; Prodrugs; cyclooxygenase-2 selective; drug design; propyphenazone

References

  1. Clin Invest Med. 1987 May;10(3):251-8 - PubMed
  2. ChemMedChem. 2013 Oct;8(10):1662-7 - PubMed
  3. Int J Cardiol. 2011 May 5;148(3):352-3 - PubMed
  4. Gastroenterology. 2000 Aug;119(2):512-20 - PubMed
  5. Digestion. 1998 Jul-Aug;59(4):298-307 - PubMed
  6. Eur J Clin Pharmacol. 1986;31(2):127-31 - PubMed
  7. Chem Pharm Bull (Tokyo). 1984 Aug;32(8):3179-86 - PubMed
  8. Eur J Med Chem. 2014 Jan;71:185-98 - PubMed
  9. J Nutr. 1988 Mar;118(3):290-6 - PubMed
  10. Gastroenterology. 1981 Jan;80(1):94-8 - PubMed
  11. Bioorg Med Chem. 2013 Jul 1;21(13):3839-49 - PubMed
  12. Dig Dis Sci. 1982 Jul;27(7):624-35 - PubMed
  13. Nature. 1996 Dec 19-26;384(6610):644-8 - PubMed
  14. Clin Ther. 2009 Nov;31(11):2618-27 - PubMed
  15. N Engl J Med. 1992 Sep 10;327(11):749-54 - PubMed
  16. Farmaco Sci. 1985 May;40(5):334-46 - PubMed
  17. Nat Struct Biol. 1996 Nov;3(11):927-33 - PubMed
  18. ACS Med Chem Lett. 2012 Sep 13;3(9):759-763 - PubMed
  19. J Vestib Res. 2013;23(3):139-51 - PubMed
  20. Eur J Clin Pharmacol. 1996;49(5):377-82 - PubMed
  21. Scand J Gastroenterol. 1995 Apr;30(4):289-99 - PubMed
  22. J Biol Chem. 2012 Jul 13;287(29):24619-30 - PubMed
  23. Baillieres Best Pract Res Clin Gastroenterol. 2000 Feb;14(1):147-59 - PubMed
  24. Clin Cornerstone. 2001;3(5):50-60 - PubMed
  25. J Pharm Pharm Sci. 2008 Sep 20;11(2):81s-110s - PubMed
  26. Mini Rev Med Chem. 2009 Jan;9(1):124-39 - PubMed
  27. J Pharm Biomed Anal. 2011 Jan 5;54(1):230-5 - PubMed
  28. J Am Coll Cardiol. 2007 Jan 2;49(1):1-14 - PubMed
  29. Gastroenterology. 1990 Apr;98(4):838-48 - PubMed
  30. Eur J Pharm Sci. 2002 Nov;17(3):121-30 - PubMed

Publication Types